Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R2-CHOP versus R-CHOP as first-line treatment for elderly patients with HIV-associated diffuse large B-cell lymphoma
ChiCTR2600132819Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine and 1 more in diffuse large B-cell lymphoma (DLBCL) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: Tumor imaging assessment results, Survival status and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
lenalidomiderituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2600132819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132819.